en · de · es · fr · pt
sr9009-notes.peptides4088.com › Data › Background And Receptor Mechanism — Hands-On Walkthrough

Background And Receptor Mechanism — Hands-On Walkthrough

By Editorial Desk · published 2025-12-23 · last reviewed 2026-02-14 · Data

A practical reference on certificate of analysis: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

Reviewed 2026-02-14. Anything still debated is marked as such rather than presented as settled.

Background and Receptor Mechanism

At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.

Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.

Background and Research Status

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.

REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.

Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.

Sr9009 at a glance

PropertyValueNotes
Chemical classSynthetic small moleculeStudied as a REV-ERB agonist
Molecular formulaC20H24ClN3O4SReported for the neutral compound
AppearanceOff-white to pale yellow solidTypical research-grade material
SolubilitySparingly soluble in waterSoluble in solvents such as DMSO
Common synonymsSR9009; StenabolicStenabolic is an informal alias

Identity, Handling, and Regulation

In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.

Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.

Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.

Related pages on this site

Regulation, Testing, and Storage

SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.

Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.

SR9009 Handling and Quality Control

Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.

SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.

Further detail

The advent of global decolonisation and the subsequent rise in prominence of the Soviet Union among several newly independent African states was viewed with wariness by the South African government. National Party politicians began warning it would be only a matter of time before they were faced with a Soviet-directed insurgency on their borders. Outlying regions in South West Africa, namely the Caprivi Strip, became the focus of massive SADF air and ground training manoeuvres, as well as heightened border patrols. A year before SWAPO made the decision to send its first SWALA recruits abroad for guerrilla training, South Africa established fortified police outposts along the Caprivi Strip for the express purpose of deterring insurgents. When SWALA cadres armed with Soviet weapons and training began to make their appearance in South West Africa, the National Party believed its fears of a local Soviet proxy force had finally been realised. The Soviet Union took a keen interest in Africa's independence movements and initially hoped that the cultivation of socialist client states on the continent would deny their economic and strategic resources to the West. Soviet training of SWALA was thus not confined to tactical matters but extended to Marxist–Leninist political theory, and the procedures for establishing an effective political-military infrastructure. In addition to training, the Soviets quickly became SWALA's leading supplier of arms and money.

Genetic vaccines are based on the principle of uptake of a nucleic acid into cells, whereupon a protein is produced according to the nucleic acid template. This protein is usually the immunodominant antigen of the pathogen or a surface protein that enables the formation of neutralizing antibodies. The subgroup of genetic vaccines encompass viral vector vaccines, RNA vaccines and DNA vaccines.

Whereas, the second but more general postulate assumes that there is no DC component unless there is an explicit DC voltage offset added to the waveforms. The latter interpretation is explained by the change to the stability diagram that results when the duty cycle moves away from d = 0.5. When this happens the range of stable q and a values for both quadrupole axes change. These changes cause the motion of ions to be more displaced along one axis compared to the other. This, consequently is the effect of the DC bias. It is important to accurately know the stability of ions inside the DIT. For example, different waveform duty cycles result in a different stability boundary. For the case of a square wave, where d = 0.5, the boundary of the first stability region crosses the

Sources: en.wikipedia.org

Background from the literature

In organisms that use chromosomal crossover to exchange DNA and recombine genes, errors in alignment during meiosis can also cause mutations. Errors in crossover are especially likely when similar sequences cause partner chromosomes to adopt a mistaken alignment; this makes some regions in genomes more prone to mutating in this way. These errors create large structural changes in DNA sequence—duplications, inversions, deletions of entire regions—or the accidental exchange of whole parts of sequences between different chromosomes, chromosomal translocation.

=== Filters === By 1959, Millipore made porous membrane filters of cellulose esters or other materials which resembled paper in sheet form, and were brittle when dry but friable when wet. Filters consisted of nitrocellulose or polycarbonate membrane nucleopore filters ranging from pore size of 0.2 μm (micrometer) to 20 μm. Modern filters are polyvinylidene fluoride and/or polypropylene based.

=== Chemical reactions === CO2 is a potent electrophile having an electrophilic reactivity that is comparable to benzaldehyde or strongly electrophilic α,β-unsaturated carbonyl compounds. However, unlike electrophiles of similar reactivity, the reactions of nucleophiles with CO2 are thermodynamically less favored and are often found to be highly reversible. The reversible reaction of carbon dioxide with amines to make carbamates is used in CO2 scrubbers and has been suggested as a possible starting point for carbon capture and storage by amine gas treating. Only very strong nucleophiles, like the carbanions provided by Grignard reagents and organolithium compounds react with CO2 to give carboxylates:

Sources: en.wikipedia.org

Further detail

The Time Machine Tour's first leg began on June 29 in Albuquerque, New Mexico and finished on October 17 in Santiago, Chile, at the National Stadium. It featured the album Moving Pictures played in its entirety, as well as "Caravan" and "BU2B". It was suggested that Rush would return to the studio after the completion of the Time Machine Tour with plans to release Clockwork Angels in 2011. However, Rush announced on November 19, 2010, that they would be extending the Time Machine Tour. The second leg began on March 30, 2011, in Fort Lauderdale, Florida and ended on July 2, 2011, in Seattle, Washington. On November 8, 2011, the band released Time Machine 2011: Live in Cleveland, a concert DVD, Blu-ray and double CD documenting the April 15, 2011, concert at the Quicken Loans Arena in Cleveland, Ohio. After the tour's second leg was finished, Rush entered Revolution Recording studios in Toronto finishing the recording of Clockwork Angels. The second single, "Headlong Flight", was released on April 19, 2012. Peart and author Kevin J. Anderson collaborated on a novelization of Clockwork Angels which was released in September 2012. Clockwork Angels was released in the U.S. and Canada on June 12, 2012, reaching No. 1 in Canada, No. 2 in the US, No. 21 in the UK and entering the Top 10 in most of Rush's traditional northern European markets. The supporting Clockwork Angels Tour began on September 7, 2012, with performances on November 25 in Phoenix and November 28 in Dallas, recorded to make a live CD/DVD/Blu-ray which was released on November 19, 2013.

The 82nd Division was redesignated on 13 February 1942 as Division Headquarters, 82nd Division, and ordered into active service on 25 March 1942, at Camp Claiborne, Louisiana, under the command of Major General Omar N. Bradley. The officer and enlisted cadre mostly came from the 9th Infantry Division. The enlisted men came from reception centers in the Midwest, South, and Southwest. During this period, the division brought together three officers who would ultimately steer the US Army during the following two decades: Matthew Ridgway, James M. Gavin, and Maxwell D. Taylor. Under Major General Bradley, the 82nd Division's Chief of staff was George Van Pope. On 15 August 1942, the 82nd Infantry Division, now commanded by Major General Ridgway, became the first airborne division in the history of the US Army, and was redesignated as the 82nd Airborne Division. The 82nd was selected after deliberations by the US Army General Staff because of a number of factors. It was not a Regular Army or National Guard unit, its personnel had all completed basic training, and it was stationed in an area that had good weather and flying facilities. Historian John B. Wilson wrote that "many traditionalists in those components wanted nothing to do with such an experimental force". James M. Gavin wrote that many states would refuse the conversion of their National Guard units, likely because of the additional expenses needed to maintain facilities for airborne units. The division initially consisted of the 325th, 326th and 327th Infantry Regiments, and supporting units.

Qi is a polysemous word that traditional Chinese medicine distinguishes as being able to transform into many different qualities of qi (气; 氣; qì). In a general sense, qi is something that is defined by five "cardinal functions":

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.

Is SR9009 a SARM?

No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.

What human data exist for SR9009?

Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.

What is SR9009?

It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.

Network